Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy.
Xuqi SunDandan HuZhoutian YangZheng LiuJuncheng WangJin-Bin ChenLi XuZhongguo ZhouMinshan ChenYao-Jun ZhangPublished in: Journal of hepatocellular carcinoma (2020)
High HBV loads did not compromise the clinical outcomes of HCC patients receiving anti-PD-1 blockade. Antiviral therapy could improve the OS of HCC patients with high HBV loads.